瑞戈非尼及其主要代谢物M-2和M-5谷浓度对化疗难治性转移性结直肠癌患者总生存期的影响:GERCOR TEXCAN多中心II期研究结果
这项前瞻性药代动力学辅助研究纳入55例化疗难治性转移性结直肠癌患者,接受瑞戈非尼160 mg/日治疗。第2周期与第1周期M-2浓度比值≥中位数的患者总生存期优于低于中位数组(12.6 vs 4.0个月,P=0.023)。第1周期瑞戈非尼+M-2+M-5总浓度在2.5-5.5 mg/L范围内时总生存期和安全性更有利。
要点
- C2/C1 M-2比值≥中位数者总生存期12.6个月,低于中位数者4.0个月(P=0.023)。
- 多因素分析中C2/C1 M-2比值≥中位数对应66%的死亡风险降低。
- C1瑞戈非尼+M-2+M-5总浓度在2.5-5.5 mg/L范围内者严重不良事件发生率降低且总生存期改善。
核心结论
- 研究识别出与瑞戈非尼治疗转移性结直肠癌患者生存获益相关的药代动力学参数。
- 当第1周期瑞戈非尼+M-2+M-5总浓度在2.5-5.5 mg/L范围内时,总生存期和安全性更有利。
- 这些结果为基于药代动力学监测的个体化瑞戈非尼剂量调整策略奠定了基础。
研究设计与样本
- TEXCAN II期GERCOR试验的前瞻性药代动力学辅助研究,纳入55例化疗难治性转移性结直肠癌患者。
- 患者接受瑞戈非尼160 mg/日,28天周期中用药21天(NCT02699073)。
- 第1周期和第2周期第15天采用液相色谱-质谱法测定瑞戈非尼、M-2、M-5浓度。
- 分析第1周期瑞戈非尼、M-2、M-5的Cmin与总生存期的关联及第1至第2周期的蓄积情况。
主要发现
- 第2周期/第1周期M-2和M-5比值中位数分别为0.82(四分位距0.50-1.78)和0.75(四分位距0.41-1.93)。
- C2/C1 M-2比值≥中位数者总生存期12.6个月,低于中位数者4.0个月(P=0.023)。
- 多因素分析中C2/C1 M-2比值≥中位数对应66%的死亡风险降低。
- C2/C1 M-2比值与第1周期瑞戈非尼+M-2+M-5总浓度相关(P=0.006)。
- 限制性立方样条分析显示C2/C1 M-2比值升高及第1周期总浓度在2.5-5.5 mg/L范围内时总生存期获益增加。
关键数值与推荐
- 第2周期/第1周期M-2比值中位数为0.82(四分位距0.50-1.78),M-5比值中位数为0.75(四分位距0.41-1.93)。
- C2/C1 M-2比值≥中位数者总生存期12.6个月 vs 低于中位数者4.0个月(P=0.023)。
- 多因素分析中C2/C1 M-2比值≥中位数对应66%的死亡风险降低。
- 第1周期瑞戈非尼+M-2+M-5总浓度在2.5-5.5 mg/L范围内者严重不良事件发生率降低且总生存期改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective pharmacokinetic (PK) ancillary study of the TEXCAN phase II GERCOR trial of patients with chemorefractory metastatic colorectal cancer and treated with regorafenib (REGO) investigated correlations between overall survival (OS) and concentrations (C) of REGO and its active metabolites, M-2 and M-5. METHODS: 55 patients received REGO 160 mg/day for 21 days of a 28-day cycle (NCT02699073). REGO, M-2, M-5 were measured by liquid chromatography-mass spectrometry assay on day 15 of cycle 1 (C1) and 2 (C2). We studied the association between OS and Cmin of REGO, M-2 and M-5 at C1 and their accumulations between C1 and C2. RESULTS: Medians of C2/C1 M-2 and M-5 ratios were 0.82 (interquartile range 0.50-1.78) and 0.75 (interquartile range 0.41-1.93), respectively. Patients with C2/C1 M-2 ratio ≥ median had improved survival compared to those < median (12.6 versus 4.0 months, P = 0.023), corresponding to a 66% mortality risk reduction in multivariate analysis. The C2/C1 M-2 ratio correlated with C1 REGO+M-2+M-5 (Csum; P = 0.006). Restricted cubic spline analysis showed an increased OS benefit as the C2/C1 M-2 ratio raises and when C1 Csum ranged between 2.5 and 5.5 mg/L. Patients within the Csum range had a reduced incidence of serious adverse events and improved OS. CONCLUSIONS: We identified PK parameters associated with a survival benefit in patients with metastatic colorectal cancer treated by REGO. OS and safety were favourable when C1 REGO+M-2+M-5 Csum ranged between 2.5 and 5.5 mg/L. These results pave the way for individual REGO dose modification strategies based on PK monitoring. CLINICAL TRIAL REFERENCE: NCT02699073.
引用
- Rousseau B, Boukerma AK, Henriques J, et al. Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. Eur J Cancer. 2022. PMID: 35489233. doi:10.1016/j.ejca.2022.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。